The European drug regulator may decide whether to approve Sanofi (NASDAQ:SNY) and partner GSK’s (NYSE:GSK) experimental COVID-19 vaccine in a few weeks, Reuters reported on Monday, citing an executive of the French drugmaker.
The companies have developed an adjuvant bivalent shot that provides protection against the Beta variant as well as the original strain of the coronavirus.
As per their collaboration, SNY provides the recombinant antigen and will be the marketing authorization holder for the vaccine, while GSK supplies its pandemic adjuvant.
In June, the firms said that the vaccine showed efficacy against the Omicron variant in a late-stage study.
Sanofi’s (SNY) executive VP for vaccines, Thomas Triomphe, told a hearing in the European Parliament that he believed the European Medicines Agency would decide on the possible approval of the vaccine in a few weeks, Reuters reported.
Triomphe said manufacturing of the vaccine had already started and deliveries to European countries could start immediately after approval, according to Reuters.
Image and article originally from seekingalpha.com. Read the original article here.